ShareValue scores for VVVV: Valuation 50, Quality 42, Growth 50, Health 41.
VVVVNYSE
vVARDIS Holding AG
$15.00
(-3.04%)
Updated
VVVVNYSE
vVARDIS Holding AG
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
Company Details
vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel. The company was incorporated in 2020 and is based in Zug, Switzerland. vVARDIS Holding AG operates as a subsidiary of VVARDIS Investment Holding AG.
Score Analysis
AI Investment Thesis
Our model rates vVARDIS Holding AG as fairly valued versus its sector, though its 57.6 P/S sits roughly 11 times the 5.1 sector average, a gap the market's post-IPO repricing partly reflects.
The decisive fundamental is profitability: a -105.16% margin against a roughly flat sector average means revenue is not yet covering costs, so the 57.6 P/S is a bet on future scale rather than current earnings.
The key event was the November 13, 2026 NYSE IPO at $18.00 per share, which raised about $175 million but closed roughly 8% below offer on debut.